0001493152-21-002458.txt : 20210203 0001493152-21-002458.hdr.sgml : 20210203 20210203090358 ACCESSION NUMBER: 0001493152-21-002458 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210203 DATE AS OF CHANGE: 20210203 EFFECTIVENESS DATE: 20210203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CANCER GENETICS, INC CENTRAL INDEX KEY: 0001349929 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 043462475 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-388238 FILM NUMBER: 21584492 BUSINESS ADDRESS: STREET 1: 201 ROUTE 17 NORTH STREET 2: 2ND FLOOR CITY: RUTHERFORD STATE: NJ ZIP: 07070 BUSINESS PHONE: 201.528.9200 MAIL ADDRESS: STREET 1: 201 ROUTE 17 NORTH STREET 2: 2ND FLOOR CITY: RUTHERFORD STATE: NJ ZIP: 07070 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS INC DATE OF NAME CHANGE: 20060117 D 1 primary_doc.xml X0708 D LIVE 0001349929 CANCER GENETICS, INC 201 ROUTE 17 NORTH 2ND FLOOR RUTHERFORD NJ NEW JERSEY 07070 201-528-9200 DELAWARE None CANCER GENETICS INC Corporation true Edmund Cannon c/o Cancer Genetics Inc. 201 Route 17 North, 2nd Floor Rutherford NJ NEW JERSEY 07070 Director Franklyn G. Prendergast c/o Cancer Genetics Inc. 201 Route 17 North, 2nd Floor Rutherford NJ NEW JERSEY 07070 Director Geoffrey Harris c/o Cancer Genetics Inc. 201 Route 17 North, 2nd Floor Rutherford NJ NEW JERSEY 07070 Director Howard McLeod c/o Cancer Genetics Inc. 201 Route 17 North, 2nd Floor Rutherford NJ NEW JERSEY 07070 Director John A. Roberts c/o Cancer Genetics Inc. 201 Route 17 North, 2nd Floor Rutherford NJ NEW JERSEY 07070 Executive Officer Biotechnology Decline to Disclose 06b false 2021-02-01 false true true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 4TH FLOOR NEW YORK NY NEW YORK 10022 CA CALIFORNIA IL ILLINOIS NV NEVADA NY NEW YORK false 10000000 10000000 0 false 6 775000 0 Excludes the value of up to 165,517 warrants issued to the Placement Agent exercisable at $4.5313 per share. 0 true Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3. false CANCER GENETICS, INC /s/ John A. Roberts John A. Roberts President and Chief Executive Officer 2021-02-03